Related references
Note: Only part of the references are listed.Safety and efficacy of tenecteplase versus alteplase in patients with acute ischaemic stroke (TRACE): a multicentre, randomised, open label, blinded-endpoint (PROBE) controlled phase II study
Shuya Li et al.
STROKE AND VASCULAR NEUROLOGY (2022)
The multiarm optimization of stroke thrombolysis phase 3 acute stroke randomized clinical trial: Rationale and methods
S. Iris Deeds et al.
INTERNATIONAL JOURNAL OF STROKE (2021)
Thrombolysis with alteplase 3-4.5 hours after acute ischaemic stroke: the first multicentre, phase III trial in China
Huaguang Zheng et al.
STROKE AND VASCULAR NEUROLOGY (2020)
Randomized trial of argatroban plus recombinant tissue-type plasminogen activator for acute ischemic stroke (ARAIS): Rationale and design
Yingying Yang et al.
AMERICAN HEART JOURNAL (2020)
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
William J. Powers et al.
STROKE (2019)
Safety and Feasibility of Argatroban, Recombinant Tissue Plasminogen Activator, and Intra-Arterial Therapy in Stroke (ARTSS-IA Study)
Ketevan Berekashvili et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2018)
Argatroban plus aspirin versus aspirin in acute ischemic stroke
Lei Chen et al.
NEUROLOGICAL RESEARCH (2018)
Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)
Andrew D. Barreto et al.
STROKE (2017)
Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials
Mayank Goyal et al.
LANCET (2016)
Direct Thrombin Inhibitor Argatroban Reduces Stroke Damage in 2 Different Models
Patrick Lyden et al.
STROKE (2014)
Defining Clinically Relevant Cerebral Hemorrhage After Thrombolytic Therapy for Stroke Analysis of the National Institute of Neurological Disorders and Stroke Tissue-Type Plasminogen Activator Trials
Neal M. Rao et al.
STROKE (2014)
An Updated Definition of Stroke for the 21st Century A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Ralph L. Sacco et al.
STROKE (2013)
The Argatroban and Tissue-Type Plasminogen Activator Stroke Study Final Results of a Pilot Safety Study
Andrew D. Barreto et al.
STROKE (2012)
Efficacy of anti-coagulant treatment with argatroban on cardioembolic stroke
Naohisa Hosomi et al.
JOURNAL OF NEUROLOGY (2007)
The impact of recanalization on ischemic stroke outcome - A meta-analysis
Joung-Ho Rha et al.
STROKE (2007)
Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment - A multicenter transcranial Doppler study
Maher Saqqur et al.
STROKE (2007)
Argatroban tPA stroke study -: Study design and results in the first treated cohort
Rebecca M. Sugg et al.
ARCHIVES OF NEUROLOGY (2006)
Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator
AV Alexandrov et al.
NEUROLOGY (2002)
Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke
JF Arenillas et al.
STROKE (2002)
Thrombolysis-related hemorrhagic infarction -: A marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion
CA Molina et al.
STROKE (2002)
Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke
DC Morris et al.
STROKE (2001)
Share Paper
